Skip to main content
SpringerLink
Log in

Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objectives

Information on the relationship between myocardial damage assessed by myocardial scintigraphy and prognosis in patients with Anderson–Fabry disease (AFD) is lacking. We therefore aimed to investigate the prognostic impacts of myocardial thallium-201 (201Tl) and iodine-123 beta-methyl 15-para-iodophenyl 3(R, S)-methylpentadecanoic acid (123I-BMIPP) dual scintigraphy in patients with AFD.

Methods

Eighteen consecutive patients with AFD underwent resting myocardial 201Tl/123I-BMIPP dual scintigraphy. Total defect scores (TDS) on both images were calculated visually according to the 17-segment model using a 5-point scoring system. The mismatch score (MS) was calculated as ‘TDS on 123I-BMIPP—TDS on 201Tl’.

Results

Six major adverse cardiac events (MACEs) were recorded during a mean follow-up of 6.7 ± 4.2 years (three heart failure requiring hospitalization and three cardiac deaths). Left ventricular mass index, left atrial diameter, brain natriuretic peptide, TDS on 123I-BMIPP, and MS were all significantly greater in patients with MACEs compared with those without. Kaplan–Meier analysis indicated that high TDS on 123I-BMIPP and high MS were associated with poor event-free survival.

Conclusion

TDS on 123I-BMIPP was a better prognostic determinant in patients with AFD than TDS on 201Tl. Myocardial 201Tl/123I-BMIPP dual scintigraphy may thus be a useful noninvasive modality for evaluating prognosis in patients with AFD.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Nakao S, Takenaka T, Maeda M, Kodama C, Tanaka A, Tahara M, et al. An atypical variant of Fabry’s disease in men with left ventricular hypertrophy. N Engl J Med. 1995;333:288–93.

    Article  CAS  Google Scholar 

  2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet. 2001;38:750–60.

    Article  CAS  Google Scholar 

  3. Kubo T, Ochi Y, Baba Y, Hirota T, Tanioka K, Yamasaki N, et al. Prevalence and clinical features of Fabry disease in Japanese male patients with diagnosis of hypertrophic cardiomyopathy. J Cardiol. 2017;69:302–7.

    Article  Google Scholar 

  4. O’Mahony C, Elliot P. Anderson-Fabry disease and the heart. Prog Cardiovasc Dis. 2010;52:326–35.

    Article  Google Scholar 

  5. Hughes DA, Elliot PM, Shah J, Zuckerman J, Coghlan G, Brookes J, et al. Effects of enzyme replacement therapy on the cardiomyopathy of Anderson-Fabry disease: a randomized, double-blind, placebo-controlled clinical trial of agalsidase alfa. Heart. 2008;94:153–8.

    Article  CAS  Google Scholar 

  6. Takenaka T, Teraguchi H, Yoshida A, Taguchi S, Ninomiya K, Umekita Y, et al. Terminal stage cardiac findings in patients with cardiac Fabry disease: an electrocardiographic, echocardiographic, and autopsy study. J Cardiol. 2008;51:50–9.

    Article  Google Scholar 

  7. Neely JR, Rovetto MJ, Oram JF. Myocardial utilization of carbohydrate and lipids. Prog Cardiovasc Dis. 1972;3:289–32929.

    Article  Google Scholar 

  8. Wakasugi S, Fischman AJ, Babich JW, Callahan RJ, Elmaleh DR, Wilkinson R, et al. Myocardial substrate utilization and left ventricular function in Adriamycin cardiomyopathy. J Nucl Med. 1993;34:1529–35.

    CAS  PubMed  Google Scholar 

  9. Narus H, Arii T, Kondo T, Morita M, Ohyanagi M, Iwasaki T, et al. Fatty acid imaging of stunned myocardium: clinical usefulness of iodine 123-labeled fatty acid imaging in patients with acute myocardial infarction. J Nucl Cardiol. 1998;5:275–84.

    Article  Google Scholar 

  10. Shimizu M, Ino H, Okeie K, Emoto Y, Yamaguchi M, Yasuda T, et al. Cardiac dysfunction and long-term prognosis in patients with nonobstructive hypertrophic cardiomyopathy and abnormal 123I–15 (p-iodophenyl)-3 (R, S) -methylpentadecanoic acid myocardial scintigraphy. Cardiology. 2000;93:43–9.

    Article  CAS  Google Scholar 

  11. Zhao C, Shuke N, Okizaki A, Yamamoto W, Sato J, Ishikawa Y, et al. Comparison of myocardial fatty acid metabolism with left ventricular function and perfusion in cariomyopathies: by 123I-BMIPP SPECT and 99mTc-tetrofosmin electrocardiographically gated SPECT. Ann Nucl Med. 2003;17:541–8.

    Article  CAS  Google Scholar 

  12. Inoue A, Fujimoto S, Yamashina S, Yamazaki J. Prediction of cardiac events in patients with dilated cardiomyopathy using 123I-BMIPP and 201Tl myocardial scintigraphy. Ann Nucl Med. 2007;21:399–404.

    Article  Google Scholar 

  13. Zavadovsky KV, Gulya MO, Lishmanov YB, Levedev DI. Perfusion and metabolic scintigraphy with 123I-BMIPP in prognosis of cardiac resynchronization therapy in patients with dilated cardiomyopathy. Ann Nucl Med. 2016;30:325–33.

    Article  CAS  Google Scholar 

  14. Nanasato M, Hirayama H, Ando A, Isobe S, Nonokawa M, Kinoshita Y, et al. Incremental predictive value of myocardial scintigraphy with 123I-BMIPP in patients with acute myocardial infarction treated with primary percutaneous coronary intervention. Eur J Nucl Med Mol Imaging. 2016;31:1512–21.

    Article  Google Scholar 

  15. Tamaki N, Tadamura E, Kudoh T, Hattori N, Yonekura Y, Nohara R, et al. Prognostic value of iodine-123 labelled BMIPP fatty acid analogue imaging in patients with myocardial infarction. Eur J Nucl Med. 1996;23:272–9.

    Article  CAS  Google Scholar 

  16. Frustaci A, Russo MA, Francone M, Chimenti C. Microvascular angina as prehypertrophic presentation of Fabry disease cardiomyopathy. Circulation. 2014;130:1530–1.

    Article  Google Scholar 

  17. Zarate YA, Hopkin RJ. Lysosomal strage disease 3. Fabry’s disease. Lancet. 2008;372:1427–35.

    Article  CAS  Google Scholar 

  18. Berman DS, Kang X, Gransar H, Gerlach J, Friedman JD, Hayes SW, et al. Quantitative assessment of myocardial perfusion abnormality on SPECT myocardial perfusion imaging is more reproducible than expert visual analysis. J Nucl Cardiol. 2009;16(1):45–53.

    Article  Google Scholar 

  19. Lang RM, Luigi PB, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular imaging. J Am Soc Echocardiogr. 2015;28:1–39.

    Article  Google Scholar 

  20. Spinelli L, Pellegrino T, Pisani A, Giudice CA, Riccio E, Imbriaco M, et al. Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2016;43:729–39.

    Article  CAS  Google Scholar 

  21. Imbriaco M, Pellegrino T, Piscopo V, Petretta M, Ponsiglione A, Nappi C, et al. Cardiac sympathetic neuronal damage precedes myocardial fibrosis in patients with Anderson-Fabry disease. Eur J Nucl Med Mol Imaging. 2017;44:2266–73.

    Article  CAS  Google Scholar 

  22. Nishimura M, Tsukamoto K, Hasebe N, Tamaki N, Kikuchi K, Ono T. Prediction of cardiac death in hemodialysis patients by myocardial fatty acid imaging. J Am Coll Cardiol. 2008;51:139–45.

    Article  CAS  Google Scholar 

  23. Barenbrock M, Spieker C, Laske V, Heidenreich S, Hohage H, Bachmann J, et al. Studies of the vessel wall properties in hemodialysis patients. Kidney Int. 1994;45:1397–400.

    Article  CAS  Google Scholar 

  24. Amman K, Breitbach M, Ritz E, Mall G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol. 1998;9:1018–22.

    Google Scholar 

  25. Nakajima K, Shimizu K, Taki J, Uetani Y, Konishi S, Tonami N, et al. Utility of iodine-123-BMIPP in the diagnosis and follow-up of vasospastic angina. J Nucl Med. 1995;36:1934–40.

    CAS  PubMed  Google Scholar 

  26. Takeishi Y, Fujiwara S, Atsumi H, Takahashi K, Sukekawa H, Tomoike H. Iodine-123-BMIPP imaging in unstable angina: a guide for interventional strategy. J Nucl Med. 1997;38:1407–11.

    CAS  PubMed  Google Scholar 

  27. Kawai Y, Tsukamoto E, Nozaki T, Morita K, Sakurai M, Tamaki N. Significance of reduced uptake of iodinated fatty acid analogue for the evaluation of patients with acute chest pain. J Am Coll Cardiol. 2001;38:1888–944.

    Article  CAS  Google Scholar 

  28. Moon JC, Sachdev B, Elkington AG, McKenna WJ, Mehta A, Pennell DJ, et al. Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Eur Heart J. 2003;24(23):2151–5.

    Article  Google Scholar 

  29. Nakajima K. Normal values for nuclear cardiology: Japanese databases for myocardial perfusion, fatty acid and sympathetic imaging and left ventricular function. Ann Nucl Med. 2010;24:125–35.

    Article  Google Scholar 

  30. Nakajima K, Matsumoto N, Kasai T, Matsuo S, Kiso K, Okuda K. Normal values standardization of parameters in nuclear cardiology: Japanese Society of Nuclear Medicine working group database. Ann Nucl Med. 2016;30:188–99.

    Article  Google Scholar 

Download references

Funding

This research received no grant from any funding agency in the public, commercial or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Department of Cardiology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 466-8560, Japan

    Tomoaki Haga, Takahiro Okumura, Satoshi Isobe, Naoaki Kano, Tasuku Kuwayama, Tsuyoshi Yokoi, Hiroaki Hiraiwa, Toru Kondo, Akinori Sawamura, Ryota Morimoto & Toyoaki Murohara

  2. Department of Cardiology, Nagoya Central Hospital, 3-7-7 Taikou, Nakamura-ku, Nagoya, Aichi, 466-8560, Japan

    Tomoaki Haga & Fuji Somura

  3. LSD Center, Nagoya Central Hospital, 3-7-7 Taikou, Nakamura-ku, Nagoya, Aichi, 466-8560, Japan

    Hiroshi Yamamoto & Kazuya Tsuboi

Authors
  1. Tomoaki Haga
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Takahiro Okumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Isobe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fuji Somura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Naoaki Kano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Tasuku Kuwayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tsuyoshi Yokoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hiroaki Hiraiwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Toru Kondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akinori Sawamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Ryota Morimoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Hiroshi Yamamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Kazuya Tsuboi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Toyoaki Murohara
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takahiro Okumura.

Ethics declarations

Conflict of interest

T.O. received lecture fees from Ono Yakuhin, Medtronics, and Otsuka, and research grants from Ono Yakuhin, Bayer, Daiichi-Sankyo, and Amgen Astellas, not in connection with the submitted work. S.I. received lecture fee from FUJIFILM RI Pharma and Nihon Medi-Physics. T.M. received lecture fees and unrestricted research grants for the Department of Cardiology, Nagoya University Graduate School of Medicine, from Bayer, Daiichi-Sankyo, Dainippon Sumitomo, Kowa, MSD, Mitsubishi Tanabe, Boehringer Ingelheim, Novartis, Pfizer, Sanofi-Aventis, Takeda, Astellas, Otsuka, and Teijin.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Haga, T., Okumura, T., Isobe, S. et al. Potential prognostic implications of myocardial thallium-201 and iodine-123-beta-methylpentadecanoic acid dual scintigraphy in patients with Anderson–Fabry disease. Ann Nucl Med 33, 930–936 (2019). https://doi.org/10.1007/s12149-019-01406-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-019-01406-0

Keywords

Search

Navigation